Biological Profiling of Endocrine Related Effects of Chemicals in ToxCastTM



RJ Kavlock, D Dix, K Houck, R Judson, T Knudsen, D Reif and M Martin

National Center for Computational Toxicology, Office of Research and Development, United States Environmental Protection Agency, Research Triangle Park, NC



Abstract

The Food Quality Protection Act of 1996 mandates that EPA implement a validated screening program for detection Act or 1996 intaindates that EPA implement a Valuations screening program for detecting estrogenic chemicals, as well as other endocrine targets deemed appropriate by the Administrator. EPA's Endocrine Disruptor Screening Program (EDSP) has been developing and validating screening assays for disruption of estrogen (E), androgen (A) and thyroid (T) signaling pathways. The EDSP includes in vitro and in vivo assays for detecting E, A or T activity; and 73 chemicals have been proposed for initial screening. ToxCast is an EPA research program using a broad range of high-throughput screens to profile the bioactivity of chemicals and develop predictive signatures of toxicity, based on modeling in vitro assay data to in vivo toxicity phenotypes. ToxCast profiled 56 of the 73 EDSP chemicals using in vitro assays which characterized receptor binding, activation, inhibition and target gene regulation, providing biological fingerprints relevant to F. A. T and other endocrine related activities. Of the over 600 ToxCast assays relevant to E, A, 1 and other endocrine related activities. Or the over 500 Tox.ast assays, six assess E, and 5 each are related to A and T receptor signaling. In addition to E, A and T endpoints, ToxCast also measured interactions with progesterone, glucocorticoid and PPAR receptors, aromatase activity, and other nuclear receptors including AhR, CAR, FXR, LXR and PXR that may modulate endocrine metabolism. Many assay targets were human proteins, but in some cases rodent or other species were targeted, affording cross species comparisons. Results for the prototypic xencestrogen bisphenol A, and the anti-androgen vinclozolin support the ability of disruptors, while screening other endpoints beyond E, A and T offers broader insights into the bioactivity of the EDSP chemicals. Although this work was reviewed by EPA and approved for publication, it may not necessarily reflect official Agency policy.





ToxCast Background

Prioritization Product Timeline

	Chemicals	Comment Comment	rupas	Assays	Chemical	Date
la.	320	Data Rich (pesticides)	Signature Development	552	\$20k	Fyee
•	15	Nanomaterials	Plus	166	\$1000	Fyee
-	-380	Data Rich Chemicals	Validation	×400	-\$20-25k	Fyee
	>100	Known Human Toxicants	Extrapolation	×400	-\$20-25k	FY09
k	-300	Expanded Structure and Use Diversity	Extension	>400	-\$20-25k	PY10
ы	×12	Nanomaterials	PMN	-200	-\$15-08K	F199-10
•	Thousands	Cuta poor	Prediction and Prioritization	×300	-\$15-00k	P111-12
FY07	FYOS	FY09	FY10)	FY11	FY12

ToxCast Phase I Datasets

ToxCast 1.0 (April, 2007)

- Cast 1.2 (June, 2008)

Approach

- Extract in vitro endpoints from ToxCast Retricted Assay Set – limited to estrogen, androgen and thyroid related assays, plus aromatase . Blinding and reporter assays from NovaScreen, Attagene, CellcDirect and the NCSC . Flag a pathway if any component assay is considered to have a 'hi'.
- Flag a pathway if any component assay is considered to have a fix Expanded Assay Set Restificted Set plus assays oncervations of the Component Assays Set Restificted Set plus assays oncervations of the Component Assays of the Component Restincted and Expanded assay clusters with multigeneration clusters derived from ToxRetDB.

Endocrine Screening

Proposed EDSP Tier 1 Battery

In vitro	
¹ Estrogen re	ceptor (ER) binding – rat uterus
Estrogen re (HeLa-9903)	ceptor a (hERe) transcriptional activation - Human cell line
Androgen re	ceptor (AR) binding – rat prostate
1,2Steroidog	enesis – Human cell line (H295R)
² Aromatase	- Human recombinant
In vivo	
Uterotrophi	: (rat)
Hershberge	r (rat)
Pubertal fen	nale (rat)
Pubertal ma	le (rat)
² Amphibian	metamorphosis (frog)
trick about	


EDSP Priority Chemicals in ToxCast Phase 1 Library



Nuclear Receptor (NR) Assays in ToxCast



ToxCast Profiling




HTS results from 14 ToxCast assays directly related to E/A/T activity. Assay are grouped left to right as androgen (4 assays), estrogen (5 assays), thyroid (4 assays) and aromatase (1 assay) related. The black bars on the left side designate occurrence of a few selected endocrinopathies seen in multi-generation studies.

HTS results from a total of 78 ToxCast assays that augment the 14 directly related to androgen, estrogen, thyroid and aromatase activities (results from those are displayed as composite pathway calls in the black bars on the left side). These new assays include a number of other nuclear receptors and cytochrome P450s. The assays are grouped by vendor source and listed alphabetically on the x-axis.

In vivo-in vitro Linkages





Strengths and Limitations of ToxCast Endocrine Profiling

Strengths
Inexpensive coverage of multiple endocrine pathways
Many assays involve human derived endocrine targets *Utilization of different technology platforms for redundancy
 *Built in redundancy supports weight of evidence interpretations *Butt in redundancy supports weight of evidence interpretating *Readily scalable to large numbers of chemicals
 *Facilitates prioritization based on biological measures
 *Adaptable to changes in technology
 *Current effort provides a priori predictions of Tier 1 results

el ack of robust intrinsic metabolic canability in most assays Lack of robust intrinsic metabolic capability in most assays
 Determination of a 'hit' in any assay dependent on a number of aspects such as potency, efficacy and curve fitting techniques
 Exclusion of endocrine feedback loops present in vivo ·Limited coverage of thyroid toxicity pathways In vivo relevance of effective in vitro concentrations unknown

necessarily reflect official Agency policy.